Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus THEOBID JR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus THEOBID JR.
AQUAPHYLLIN vs THEOBID JR.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Inhibits phosphodiesterase, increasing intracellular cAMP; causes bronchodilation, central nervous system stimulation, and positive inotropic/chronotropic effects.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
300 mg orally every 12 hours, extended-release tablet. Titrate to serum theophylline concentration of 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
3-8 hours in adults; prolonged in neonates, cirrhosis, heart failure (up to 30 hours). Tobacco smoking induces clearance (half-life 4-5 hours).
Renal: 90-95% unchanged; biliary/fecal: <5%.
Hepatic metabolism (90%), renal excretion of unchanged drug (10%). Metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator